recombinant influenza ha vaccine (h5n1)

Recombinant influenza HA vaccine (H5N1) is a type of vaccine designed to provide active immunization against the influenza A virus subtype H5N1, commonly known as highly pathogenic avian influenza or bird flu. This vaccine typically utilizes recombinant technology to produce the hemagglutinin (HA) protein of the H5N1 virus, which serves as the primary viral antigen. Upon administration, the vaccine stimulates the immune system to produce antibodies specifically targeting the H5 hemagglutinin. These antibodies work by blocking the virus's ability to attach to host cells, thereby neutralizing its infectivity and preventing disease. Recombinant HA vaccines offer advantages such as faster production timelines compared to traditional egg-based methods and can be formulated with adjuvants to enhance immunogenicity and broaden immune responses. They are primarily intended for individuals at increased risk of exposure to the H5N1 virus, and some formulations are also developed for veterinary use in poultry.

Brand names

AudenzAflunovCelldemicIncellipanAdjupanrixFocliviaArepanrixPanvaxPumarix

Other names

H5N1 vaccineH-5N1 vaccineH 5N1 vaccineInfluenza A (H5N1) Vaccineavian influenza H5N1 vaccine